NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) — ANEW MEDICAL, INC. (ANEW or the Firm) (NASDAQ: WENA) a U.S. -based biotechnology firm centered on creating cell and gene-based remedies for growing older, and age-related illnesses, in the present day introduced the grant and issuance of U.S. Patent No. 12,036,268 (the 268 patent) masking the secreted RNA splice variant of the human Klotho gene, known as s-KL, for the therapy of cognitive and neurodegenerative illnesses.
The human Klotho gene, typically known as the anti-aging gene, additionally controls many regular mind and neurologic features. The Klotho gene-therapy patent within the U.S. is instrumental new mental property (IP) defending its improvement and commercialization within the U.S. ANEW beforehand introduced that patents have already been granted and issued in Europe, China, and different Asian markets.
ANEW’s IP portfolio has been licensed on an unique worldwide foundation from the Universitat Autònoma de Barcelona (UAB) and Institució Catalana De Recerca Estudis Avançats (ICREA) in Barcelona, Spain, and offers ANEW with rights to develop and commercialize novel genetic approaches for the therapy of neurodegenerative illnesses, together with Alzheimer’s, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s illness), Parkinson’s illness, and different age-related issues. Changing or augmenting the manufacturing of the gene product, s-KL, may be used to help longevity.
This can be a main win for ANEW and our shareholders, commented Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. It offers us with the safety we have to efficiently transfer ahead with the event of our progressive protein, cell and gene therapies utilizing our patented sequence and use of s-KL secreted Klotho RNA splice variant sequence and supply methods to deal with these devastating neurodegenerative illnesses. With the issuance of this essential patent within the USA, ANEW has secured an enviable international IP place with patents already issued in Europe, China, Hong Kong, and Japan.
About ANEW MEDICAL, INC.
ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical firm specializing within the improvement of patented, novel disease-modifying applied sciences concentrating on the mind and central nervous system (CNS) which are seen as key developments in treating neurodegenerative and age-related issues. The Firm obtained unique worldwide rights to platform applied sciences and knowhow to develop leading edge protein, gene and cell therapies to deal with age-related pathologies corresponding to Alzheimer’s and Parkinson’s Illness, ALS, a number of sclerosis and uncommon neurodegenerative illnesses. The corporate is managed by a crew of people and advisors who’re extremely skilled in biopharmaceutical product improvement and commercialization.
For extra info, contact:
Eric Boyd
Investor Relations
E mail: IR@anewmeds.com
Ahead-Trying Statements:
This press launch accommodates forward-looking statements. These statements are made beneath the secure harbor provisions of the U.S. Non-public Securities Litigation Reform Act of 1995. These forward-looking statements usually are recognized by the phrases consider, challenge, count on, anticipate, estimate, intend, technique, future, alternative, plan, might, ought to, will, would, shall be, will proceed, will probably end result, and comparable expressions. With out limiting the generality of the foregoing, the forward-looking statements on this press launch embrace descriptions of the Firm’s future business operations. Ahead-looking statements are predictions, projections and different statements about future occasions which are based mostly on present expectations and assumptions and, because of this, are topic to dangers and uncertainties. Many elements might trigger precise future occasions to vary materially from the forward-looking statements on this press launch, such because the Firm’s incapability to implement its enterprise plans, determine and notice extra alternatives, or meet or exceed its monetary projections and modifications within the regulatory or aggressive atmosphere during which the Firm operates. You need to rigorously take into account the foregoing elements and the opposite dangers and uncertainties described within the paperwork filed or to be filed by the Firm with the U.S. Securities and Change Fee (the SEC) infrequently, which might trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Copies of those paperwork can be found on the SEC’s web site, www.sec.gov. All info supplied herein is as of the date of this press launch, and the Firm undertakes no obligation to replace any forward-looking assertion, besides as required beneath relevant regulation.
Supply: ANEW MEDICAL, INC.
